Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Nat Rev Drug Discov. 2016 Nov 3;16(3):181–202. doi: 10.1038/nrd.2016.199

Figure 2. Schematics of bivalent RNA aptamers used as agonists.

Figure 2

A) The bivalent 4-1BB aptamer. The 3′-terminus of two 4-1BB aptamers are attached to a 21-nt complementary linker sequence and subsequently annealed together. B) The bivalent OX40 aptamer. The 3′-end linker sequences (20 nt in length) of OX40 aptamers were annealed to a flexible DNA scaffold. A tandem repeat of 20 nt DNA oligos was connected by a flexible polyethylene spacer.

HHS Vulnerability Disclosure